We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Comparative Study of ALX-0081 Versus GPIIb/IIIa Inhibitor in High Risk Percutaneous Coronary Intervention (PCI) Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01020383
Recruitment Status : Completed
First Posted : November 24, 2009
Last Update Posted : July 12, 2012
Information provided by (Responsible Party):

Brief Summary:

This is a multicenter, randomized and open-label Phase II study to compare the safety, tolerability and biological effectiveness of ALX-0081 versus the GPIIb/IIIa inhibitor ReoPro® in high risk PCI patients.

Patients will receive standard treatment with acetylsalicylic acid (ASA) plus clopidogrel and heparin. Eligible patients will be randomly assigned to receive open-label study treatment with either ALX-0081 or ReoPro®. Patients will be stratified according to PCI type (elective or ad-hoc) and stent type (bare metal stent or drug eluting stent).

Condition or disease Intervention/treatment Phase
Unstable Angina Non ST Segment Elevation Myocardial Infarction (NSTEMI) Stable Angina (Associated With High Risk PCI) Drug: ALX-0081 Drug: ReoPro® Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 364 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2 Randomized, Open Label Clinical Trial in High Risk Percutaneous Coronary Intervention (PCI) Patients Receiving Standard Antithrombotic Treatment Plus Either ALX-0081 or GPIIb/IIIa Inhibitor (ReoPro®) Over a Period of 24 Hours
Study Start Date : September 2009
Primary Completion Date : May 2011
Study Completion Date : March 2012

Resource links provided by the National Library of Medicine

Drug Information available for: Abciximab
U.S. FDA Resources

Arm Intervention/treatment
Experimental: ALX-0081 Drug: ALX-0081
4 i.v. bolus injections, once every 6 hours; first dose of 6 mg, three subsequent doses of 4 mg
Active Comparator: GPIIb/IIIa inhibitor Drug: ReoPro®
0.25 mg/kg i.v. bolus injection followed by continuous i.v. infusion of 0.125 µg/kg/min (to a max. of 10 µg/min) for 12 hours

Primary Outcome Measures :
  1. Incidence and severity of bleeding classified by the following criteria: TIMI major bleeding events, TIMI minor bleeding events, bleeding events requiring medical attention, defined as TIMI minimal bleeding events [ Time Frame: 30 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Have unstable angina or NSTEMI,or stable angina with at least 2 factors indicating a high risk PCI as follows: patient related: diabetic patients, renal failure (glomerular filtration rate < 60), reduced left ventricular ejection fraction < 35%, age > 75 years, female gender and/or lesion/anatomy related: SYNTAX score > 26, bifurcation lesions, multi-vessel disease, intracoronary thrombus.
  • Adequate hematological function including platelets > 100000/mm3.
  • Body mass index (BMI) ≥18 kg/m2 and ≤ 35 kg/m2.
  • Aged ≥ 18 years old.
  • Women of childbearing potential must be practicing a medically acceptable contraceptive regimen. Only males who do not want to father children during the study and in the first 4 months after treatment may be included in the study. During this period, safe contraception is mandatory. Male patients who are sexually active must use a condom during intercourse and ensure that the female partner uses a reliable contraceptive method, or they must refrain from sexual intercourse during the first 4 months after treatment.
  • Patients must be accessible for follow-up.
  • Have a sufficient command to read and understand all instructions necessary for giving informed consent and participating in the study.
  • Have signed and dated written informed consent prior to any study-related procedures.

Exclusion Criteria:

  • Previous (within 30 days) treatment with GPIIb/IIIa inhibitors (such as ReoPro®).
  • ST-elevation myocardial infarction (STEMI).
  • Chronic total occlusion of a coronary artery.
  • Scheduled rotablator procedure.
  • PCI of the arterial or venous by-pass graft.
  • Any contra-indication for ReoPro®.
  • Major organ dysfunction, infection or any serious underlying medical condition that would impair the ability of the patient to receive protocol treatment.
  • Known hypersensitivity to human/humanized antibodies.
  • Women who are pregnant or lactating.
  • Dementia or significantly altered mental status that would prohibit understanding the study procedures and giving informed consent.
  • Use of vitamin K antagonists and/or Factor Xa inhibitors within 4 weeks prior to admission to the Hospital Intensive Care Unit.
  • Use of GPIIa/IIIb inhibitors other than ReoPro®; prasugrel, bivalirudin and fondaparinux prior to and throughout the study.
  • Known history of acquired or congenital bleeding disorder, coagulopathy or platelet disorder.
  • Evidence of active pathological bleeding at screening or history of clinically significant bleeding (such as gastrointestinal or genitourinary) within the last 6 months prior to screening visit, unless the cause has been definitely corrected
  • History of intracranial bleeding (e.g. hemorrhagic stroke, subdural hematoma, subarachnoid hemorrhage) or history of hemorrhagic retinopathy.
  • History of ischemic stroke or TIA, within the past year prior to screening or known structural cerebral vascular lesion (e.g. arteriovenous malformation, aneurysm).
  • History of New York Heart Association class III or IV congestive heart failure or history of severe, uncontrolled cardiac arrhythmias at screening.
  • Planned elective surgical operation or major invasive procedures or traumas from 30 days prior to screening to completion of the study at Day 30 (the decision of what constitutes a major invasive procedure or trauma will be at the discretion of the investigator in conjunction with review and approval by the Medical Monitor).
  • Use of another investigational drug or device within previous 30 days (12 weeks for investigational devices, e.g. unapproved stents) prior to screening.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01020383

  Show 39 Study Locations
Sponsors and Collaborators
Study Director: Josefin-Beate Holz, MD Ablynx NV

Responsible Party: Ablynx
ClinicalTrials.gov Identifier: NCT01020383     History of Changes
Other Study ID Numbers: ALX-0081-2.1/09
First Posted: November 24, 2009    Key Record Dates
Last Update Posted: July 12, 2012
Last Verified: July 2012

Additional relevant MeSH terms:
Myocardial Infarction
Angina Pectoris
Angina, Stable
Angina, Unstable
Pathologic Processes
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Chest Pain
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Platelet Aggregation Inhibitors